As of my research, there have been no recent updates on the approval status of Lurbinectedin. The sources you provided do not contain any information regarding the current approval status of the drug.

The first source, Drug Patent Watch, provides information about the drug Lurbinectedin, including its patent status and expiration date [1]. However, it does not provide any updates on its approval status.

The second source, a publication on PubMed, discusses the potential therapeutic effects of Lurbinectedin in treating ovarian cancer [2]. While the study provides valuable information about the drug's efficacy, it does not mention its approval status.

The third source, a publication on PMC (PubMed Central), explores the potential use of Lurbinectedin in treating various types of cancer, including small cell lung cancer and ovarian cancer [3]. However, it does not provide any updates on the drug's approval status.

To obtain the most up-to-date information on the approval status of Lurbinectedin, it is recommended to consult official sources such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These regulatory agencies are responsible for reviewing and approving new drugs for market availability.

In conclusion, based on the provided sources, there have been no recent updates on the approval status of Lurbinectedin. For the latest information, it is advisable to refer to official regulatory agencies or reliable medical news sources.

Sources:
[1] Drug Patent Watch. Lurbinectedin Tradename Information. Retrieved from: https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] PubMed. Potential Therapeutic Effects of Lurbinectedin on Ovarian Cancer. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/32816202/
[3] PMC. Lurbinectedin: A New Antitumoral Agent. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532454/